文献速递淋巴瘤

CT-P10与利妥昔单抗治疗晚期滤泡性淋巴瘤的长期疗效与安全性:随机3期研究

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.
PubMed 文献 · Blood Adv · 2021-01-01

这项双盲、平行组3期试验将140例晚期惰性B细胞淋巴瘤(含1-3a级滤泡性淋巴瘤)患者随机分配接受CT-P10或利妥昔单抗联合CVP方案诱导治疗8周期,缓解者继续维持治疗2年。

要点

  • CT-P10与利妥昔单抗在晚期滤泡性淋巴瘤中长期疗效相当
  • 4年无进展生存率和总生存率组间无显著差异
  • 两组治疗期间不良事件发生率及长期安全谱相似

核心结论

  • CT-P10治疗晚期滤泡性淋巴瘤患者结局良好,与利妥昔单抗长期疗效和总体安全性相当。

研究设计与样本

  • 双盲、平行组3期随机试验,纳入140例≥18岁III-IV期惰性B细胞淋巴瘤(含1-3a级滤泡性淋巴瘤)患者,1:1随机接受CT-P10或利妥昔单抗(375 mg/m2 IV)联合环磷酰胺、长春新碱、泼尼松每3周共8周期诱导,缓解者维持治疗2年。

主要发现

  • 治疗期间不良事件发生率CT-P10组90%、利妥昔单抗组86%,两组长期安全谱相似。

关键数值与推荐

  • 诱导期总缓解率(PR+CR)按2007 IWG标准评估。
  • 无进展生存和总生存按1999 IWG标准评估。

临床怎么用

  • CT-P10可作为利妥昔单抗的生物类似药用于晚期滤泡性淋巴瘤的联合化疗及维持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab biosimilars are a cornerstone of treatment of advanced-stage follicular lymphoma (FL). This double-blind, parallel-group, phase 3 trial randomized (1:1) adults (≥18 years) with stage III to IV indolent B-cell lymphoma, including grades 1 to 3a FL, to receive CT-P10 or rituximab (375 mg/m2 IV), with cyclophosphamide, vincristine, and prednisone, every 3 weeks for 8 cycles (induction period). Patients achieving complete response (CR), unconfirmed CR, or partial response (PR) received CT-P10 or rituximab maintenance for 2 years (375 mg/m2, every 8 weeks). Primary end points were previously reported, proving noninferiority of efficacy and pharmacokinetic equivalence of CT-P10 to rituximab. Secondary end points included overall response rate (PR+CR) during the induction period per 2007 International Working Group (IWG) criteria, survival analyses, and overall safety. Between 28 July 2014 and 29 December 2015, 140 patients were randomized (70 per group). Median follow-up was 39.9 months (interquartile range, 36.7-43.5). Per 1999 IWG criteria, 4-year Kaplan-Meier estimates (95% confidence interval [CI]) for CT-P10 and rituximab were 61% (47% to 73%) and 55% (36% to 70%) for progression-free survival (hazard ratio, 1.33 [95% CI, 0.67-2.63]; P=.409), respectively, and 88% (77% to 94%) and 93% (83% to 97%) for overall survival (5.29 [0.84-33.53]; P=.077). Overall, 90% (CT-P10) and 86% (rituximab) of patients experienced treatment-emergent adverse events. Long-term safety profiles were similar between groups. Findings confirm favorable outcomes for CT-P10-treated patients with advanced-stage FL and demonstrate comparable long-term efficacy and overall safety between CT-P10 and rituximab. This trial was registered at www.clinicaltrials.gov as #NCT02162771.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Buske C, Jurczak W, Sancho JM, et al. Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. Blood Adv. 2021. PMID: 34477816. doi:10.1182/bloodadvances.2021004484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。